Download PDF
Thromb Haemost 2002; 87(03): 502-508
DOI: 10.1055/s-0037-1613031
Review Article
Schattauer GmbH

Immunoglobulin G from Patients with Antiphospholipid Syndrome Impairs the Fibrin Dissolution with Plasmin

Krasimir Kolev
1   Semmelweis University, Department of Medical Biochemistry
,
Judit Gombás
1   Semmelweis University, Department of Medical Biochemistry
,
Balázs Váradi
1   Semmelweis University, Department of Medical Biochemistry
,
Judit Skopá
2   National Stroke Center
,
Katalin Mede
2   National Stroke Center
,
Ervin Pitlik
3   Semme lweis University, 2nd Department of Internal Medicine, Budapest, Hungary
,
Zoltán Nagy
2   National Stroke Center
,
Raymund Machovich
1   Semmelweis University, Department of Medical Biochemistry
› Author Affiliations
Further Information

Publication History

Received 12 June 2001

Accepted after resubmission 28 November 2001

Publication Date:
14 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Immunoglobulin G (IgG) isolated from normal human blood plasma stabilizes the structure of perfused crosslinked fibrin and prolongs the time for its dissolution with plasmin, when the fibrin surface is exposed to 500 s-1 shear rate flow. The IgG from patients suffering in antiphospholipid syndrome with thrombotic complications exerts even stronger antifibrinolytic effect. A patient, whose IgG does not affect the fibrin dissolution with plasmin, displays a bleeding tendency. The shear stress-induced disassembly of the fibrin clots containing IgGs with antifibrinolytic potency occurs at a much more advanced stage of fibrin digestion, as evidenced by the electrophoretic pattern of the ureatreated samples. The antifibrinolytic effects are also produced under static conditions and these are caused by the variable portion of the IgG molecules (fragment Fab), whereas the constant part (fragment Fc) has no inhibitory effect. The IgGs with antifibrinolytic properties do not affect directly the plasmin activity in amidolytic assay, but the IgGs from APS patients obliterate the competition of the fibrin and the peptidyl-p-nitroanilide for the protease in the same assay system suggesting interference of the IgGs with the plasmin action on the fibrin substrate. Thus, the correlation of the clinical symptoms with the effect of the isolated IgG on the dissolution of perfused fibrin clots supports a physiological and a pathological role of IgG in the fibrinolytic process related to the variability of the cross-reactions of immunoglobulins with fibrin, fibrin degradation products or fibrin-plasmin complexes.

Keywords

Antiphospholipid syndrome - immunoglobulin G - fibrin - plasmin - fibrinolysis
 

  • References

  • 1 Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med 1996; 47: 533-53.
    CrossrefPubMedSearch in Google Scholar
  • 2 Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 2149-57.
    PubMedSearch in Google Scholar
  • 3 Rand JH, Wu XX. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999; 82: 649-55.
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Roubey RAS. Immunology of the antiphospholipid syndrome: antibodies, antigens and autoimmune response. Thromb Haemost 1999; 82: 656-61.
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Ieko M, Sawada K, Koike T, Notoya A, Mukai M, Kohno M, Wada N, Itoh T, Yoshioka N. The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. Semin Thromb Hemost 1999; 25: 503-7.
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Cugno M, Dominguez M, Cabibbe M, Bisiani G, Galli M, Angles-Cano E, Agostoni A. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Brit J Haematol 2000; 108: 871-5.
    CrossrefPubMedSearch in Google Scholar
  • 7 Ames PRJ, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies – a crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76: 190-4.
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Scorer AE. Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody. Thromb Res 1997; 85: 295-304.
    CrossrefPubMedSearch in Google Scholar
  • 9 Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-9.
    PubMedSearch in Google Scholar
  • 10 Harris EN. The Second International Anticardiolipin Standardization Workshop/The Kaps Group. Am J Clin Pathol 1990; 94: 476-84.
    CrossrefPubMedSearch in Google Scholar
  • 11 Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants. Thromb Haemost 1995; 74: 1597-603.
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Steiner LA, Lowey S. Optical rotatory dispersion studies of rabbit )’Gimmunoglobulin and its papain fragments. J Biol Chem 1966; 241: 231-40.
    PubMedSearch in Google Scholar
  • 13 Porter RR. The hydrolysis of rabbit )’-globulin and antibodies with crystalline papain. Biochem J 1959; 73: 119-26.
    CrossrefPubMedSearch in Google Scholar
  • 14 Kouki T, Inui T, Yamashiro K, Hachiya T, Ochi Y, Kaajita Y, Takasu N, Sato Y, Hagata A. Demonstration of fragments with thyroid stimulating activity from thyroid stimulation blocking antibodies-IgG molecules by papain digestion. Clin Endocrinol 1997; 47: 693-8.
    CrossrefPubMedSearch in Google Scholar
  • 15 Komorowicz E, Kolev K, Léránt I, Machovich R. Flow-rate modulated dissolution of fibrin with clot-embedded and circulating proteases. Circ Res 1998; 82: 1102-8.
    CrossrefPubMedSearch in Google Scholar
  • 16 Komorowicz E, Kolev K, Machovich R. Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors. Biochemistry 1998; 37: 9112-8.
    CrossrefPubMedSearch in Google Scholar
  • 17 Kolev K, Léránt I, Tenekejiev K, Machovich R. Regulation of the fibrinolytic activity of neutrophil leukocyte elastase, plasmin and miniplasmin by plasma protease inhibitors. J Biol Chem 1994; 269: 17030-4.
    PubMedSearch in Google Scholar
  • 18 Kolev K, Komorowicz E, Owen WG, Machovich R. Quantitative comparison of fibrin degradation with plasmin, miniplasmin, neutrophil leukocyte elastase and cathepsin G. Thromb Haemost 1996; 75: 140-6.
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Inglese J, Samama P, Patel S, Burbaum J, Stroke IL, Appel KC. Chemokine receptor-ligand interactions measured using time-resolved fluorescence. Biochemistry 1998; 37: 2372-7.
    CrossrefPubMedSearch in Google Scholar
  • 20 Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites and species differences. Biochemistry 1980; 19: 1013-9.
    CrossrefPubMedSearch in Google Scholar
  • 21 Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999; 274: 5201-12.
    CrossrefPubMedSearch in Google Scholar
  • 22 Dominguez M, Cacoub P, de la Torre IG, Piette JC, Salazar-Paramo M, vGodeau P, Angles-Cano E. Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases. J Rheumatol 2001; 28: 302-8.
    PubMedSearch in Google Scholar
  • 23 Puurunen M, Palosuo T, Lassila R, Anttila M, Vaarala O. Immunological and hematological properties of antibodies to prothrombin and plasminogen in a mouse model. Lupus 2001; 10: 108-15.
    CrossrefPubMedSearch in Google Scholar
  • 24 Carr ME, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 1996; 128: 83-8.
    CrossrefPubMedSearch in Google Scholar
  • 25 Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
    PubMedSearch in Google Scholar
  • 26 Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med 1983; 01: 545-52.
    PubMedSearch in Google Scholar
  • 27 O’Kane MJ, Wisdom GB, Desai ZR, Archbold GPR. Inhibition of fibrin monomer polymerization by myeloma immunoglobulin. J Clin Pathol 1994; 47: 266-8.
    CrossrefPubMedSearch in Google Scholar
  • 28 Kolev K, Tenekedjiev K, Komorowicz E, Machovich R. Functional evaluation of the structural features of proteases and their substrate in fibrin surface degradation. J Biol Chem 1997; 272: 13666-75.
    CrossrefPubMedSearch in Google Scholar
  • 29 Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed. Dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
    CrossrefPubMedSearch in Google Scholar
  • 30 Carr ME, Gabriel DA. The effect of dextran 70 on the structure of plasmaderived fibrin gels. J Lab Clin Med 1980; 96: 985-93.
    PubMedSearch in Google Scholar